Expert opinions · patient guide

Prostate cancer: what an expert review can clarify

An expert review of prostate cancer records is most useful when it answers a specific decision: whether the risk group and stage are clear, whether the treatment options you were offered fit that picture, and what information is still missing. It does not replace examination by the treating team, and it does not by itself confirm hospital acceptance or treatment availability in China.

Go to the practical guidance ↓
AI illustration: Desk with medical clipboard, pen, stethoscope, eyeglasses, and books near a window with a traditional building outside.
AI-generated illustration for care planning; not a photograph of a real patient, clinician or hospital, and not a diagnostic image.
In this guide

What an expert review is actually for

Prostate cancer decisions rarely hinge on one number. They combine the PSA level, the grade of the cancer on biopsy (the Gleason score or Grade Group), how far the disease appears to extend on imaging, the man's age and general health, and what matters most to him about urinary, sexual and bowel function. A records-based review takes those pieces and asks whether they fit together and whether the plan follows from them.

That is different from a first appointment. A clinician meeting you in person can examine you, order tests and take responsibility for treatment. A review conducted from documents works at a distance: it can identify inconsistencies, point out where the evidence is thin, and frame the questions that a treating team should answer. It cannot confirm fitness for a specific operation or guarantee that a hospital will accept you.

The most productive reviews start with a question the patient can state plainly. "Is my cancer low-risk or intermediate-risk, and does that change whether I need treatment now?" is a reviewable question. "What is the best treatment?" is too broad to answer well from paper alone, because the answer depends on preferences and clinical findings the reviewer may not have.

The records that make a review meaningful

A review is only as good as the material it works from. For prostate cancer, the core set is usually the pathology report from the diagnostic biopsy (including the Gleason score, number of cores taken and number positive, and the percentage of cancer in each core), the PSA history with dates, and the imaging reports used for staging. If a prostate MRI was done before biopsy, that report matters too, because it describes the lesion's location and suspicion score.

The treatment history matters as much as the diagnosis. If you have already had surgery, radiotherapy or hormone treatment, the reviewer needs the operative note or discharge summary, the radiotherapy plan and dose if available, and the PSA values after treatment. A rising PSA after treatment raises a different set of questions from a newly diagnosed cancer, and mixing the two leads to confused advice.

It helps to send a short summary in your own words: when the cancer was found, what has been done, what you have been told, and what you want clarified. Ask the receiving service which documents it needs and in what form. Do not send passport numbers, payment details or a complete archive at the first contact; a brief summary and a list of available reports is enough to begin.

One practical caution: reports in another language may need translation, and the quality of that translation affects the review. Ask whether translated pathology and imaging reports are acceptable and who is responsible for accuracy.

Risk group, stage and what the reviewer can check

Much of prostate cancer planning rests on classifying the disease into a risk group and a stage. Risk grouping combines PSA, Grade Group and clinical stage, and it drives whether active surveillance, surgery, radiotherapy or systemic treatment is discussed first. A review can check whether the stated risk group matches the underlying data, and whether the staging imaging is adequate for the decision being made.

This is where reviews often add value. A pathology report may describe a Grade Group that sits at a boundary, or the biopsy sampling may be limited, and a second look at the slides by an experienced pathologist can change the picture. Staging imaging may have been done with one modality when another would answer a specific question better. These are not decisions the reviewer makes for you; they are points to raise with the team that will treat you.

The reviewer can also flag what is missing. If no staging imaging has been reported, or if the PSA history is a single value without dates, the review should say so rather than fill the gap with assumption. Ask for a written summary of what the review concluded and what it could not conclude. That document is more useful to your treating team than a verbal impression.

Treatment options: what a review can and cannot settle

For localised prostate cancer, the main options discussed in guidelines include active surveillance for lower-risk disease, radical prostatectomy, and radiotherapy, sometimes with hormone treatment. Each has a different pattern of urinary, sexual and bowel effects, and the trade-offs depend on the individual. A review can explain how the guidelines map onto your risk group and can identify questions you should ask about each option, such as what the expected functional impact is likely to be in your case and what follow-up looks like.

What a review cannot do is decide for you. It also cannot promise an outcome. Nerve-sparing during surgery, for example, depends on the location and extent of the cancer and is a judgement the operating surgeon makes, often with information only available at the time of operation. Similarly, whether active surveillance is safe depends on the reliability of the biopsy sampling and the follow-up plan, which the treating team must confirm.

If you have advanced or recurrent disease, the review may focus on whether the systemic treatment sequence matches current evidence and whether relevant testing, such as genomic or imaging assessment, has been considered. These are questions for the treating clinicians; the review's role is to make sure the questions are asked with the right records in hand.

Be wary of any review that offers a definitive recommendation without seeing the pathology slides and imaging. Ask what the reviewer actually examined.

How a review fits with care in China

Some international patients seek a review before deciding whether to travel for treatment in China. The review can help clarify the clinical picture and prepare a focused set of questions, but it does not establish that a particular hospital will accept the case or that a specific treatment is available. Those are decisions for the hospital and its clinicians after they assess the records and, where needed, the patient.

If travel is being considered, the practical questions to confirm with the provider include which hospital and department would see the case, what records they require, whether an interpreter is needed for consultations, and what the written treatment plan and fee scope would include. Ask for those details in writing rather than relying on general impressions. Hospital consultation and treatment fees are separate from any coordination service, and the actual quote should state what it covers.

For patients who want a records-based opinion while remaining at home, a proxy consultation is one route; it is optional and not a prerequisite for an appointment or operation. A multidisciplinary review involving several specialties may suit complex cases, with scope and fee agreed in advance. An initial enquiry is free and asks only for a brief summary.

Related treatment reference

Questions to put to the treating team

Whether you use a review or go straight to a consultation, the same questions tend to matter. What is my risk group and stage, and what evidence supports that classification? Which treatment options fit my situation, and what are the expected effects on urinary, sexual and bowel function? What follow-up will be needed, and how will we know whether treatment has worked? If active surveillance is proposed, what would prompt a change of plan?

It is reasonable to ask your clinician about the chance of benefit and the chance of side effects for each option, and to ask how those estimates apply to someone with your particular findings. No estimate guarantees an individual result, but a clear discussion of risk is part of good care.

Finally, ask what the review or consultation did not cover. A candid answer tells you where the uncertainty lies and what to do next. If symptoms are worsening or you have new pain, urinary retention or other urgent problems, seek local medical care rather than waiting for an overseas review.

To begin, send a brief summary of the diagnosis, the main question and a list of available reports through the enquiry form, email or WhatsApp. The team will identify missing information and suggest a relevant next step; the hospital and its clinicians decide suitability and treatment.

Sources & scope of this guide

References and official service information relevant to this guide.

  1. Related treatment reference
  2. EAU Guidelines on Prostate Cancer
  3. NICE guideline NG131: Prostate cancer diagnosis and management
  4. NCI Prostate Cancer Treatment (PDQ) – Health Professional Version

This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.